We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$8.5B
$26.8M 0.1%
136,404
-38,780
-22% -$8.04M
FLGT icon
52
Fulgent Genetics
FLGT
$558M
$25.8M 0.1%
495,573
-50,616
-9% -$2.12M
ADPT icon
53
Adaptive Biotechnologies
ADPT
$3.61B
$22.5M 0.08%
379,682
-60,857
-14% -$3.14M
VSTM icon
54
Verastem
VSTM
$528M
$21.6M 0.08%
+845,337
New +$17M
MREO
55
Mereo BioPharma
MREO
$48.9M
$21.6M 0.08%
+6,030,293
New +$15.1M
ALT icon
56
Altimmune
ALT
$568M
$21.3M 0.08%
1,884,451
-322,504
-15% -$3.8M
AUPH icon
57
Aurinia Pharmaceuticals
AUPH
$1.95B
$19.5M 0.07%
1,410,064
-207,965
-13% -$3.03M
IMTX icon
58
Immatics
IMTX
$1.23B
$19.5M 0.07%
1,805,025
+803,611
+80% +$8.47M
NVAX icon
59
Novavax
NVAX
$1.21B
$18.9M 0.07%
169,706
-17,670
-9% -$1.88M
ACGN
60
DELISTED
Aceragen Inc
ACGN
$16.9M 0.06%
271,376
– –
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$16.6M 0.06%
2,893,276
-359,266
-11% -$2.72M
XNCR icon
62
Xencor
XNCR
$1.45B
$16.1M 0.06%
369,370
-40,772
-10% -$1.69M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$15.5M 0.06%
412,466
-136,581
-25% -$4.97M
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.4M 0.05%
857,339
-92,484
-10% -$1.08M
GWPH
65
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13M 0.05%
112,897
-25,848
-19% -$2.9M
GMDA
66
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$13M 0.05%
1,548,314
+914,990
+144% +$6.19M
KDNY
67
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.9M 0.04%
+748,693
New +$11.3M
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$11.4M 0.04%
+668,000
New +$8.37M
MIRM icon
69
Mirum Pharmaceuticals
MIRM
$6.56B
$11.3M 0.04%
647,313
+94,304
+17% +$1.85M
SPRY icon
70
ARS Pharmaceuticals
SPRY
$579M
$11M 0.04%
+238,095
New +$7.95M
XENE icon
71
Xenon Pharmaceuticals
XENE
$6.1B
$10.6M 0.04%
687,386
-72,922
-10% -$853K
BLUE
72
DELISTED
bluebird bio
BLUE
$9.82M 0.04%
17,523
-1,931
-10% -$1.22M
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.72M 0.04%
1,406,037
– –
ASMB icon
74
Assembly Biosciences
ASMB
$498M
$9.33M 0.04%
128,452
– –
ANAB icon
75
AnaptysBio
ANAB
$1.54B
$9.18M 0.03%
427,179
-60,064
-12% -$1.46M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.